Tempus AI TEM is currently in its 10 th year of business and on track to hit a long-anticipated milestone. In its first-quarter 2025 earnings report, the AI-driven healthcare company guided full-year ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Tempus AI’s core clinical diagnostics business grew 31% year over year, supported by a 20% volume expansion. Meanwhile, hereditary testing, stemming from the legacy Ambry Genetics business ...

said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would represent an 80 percent growth year-on-year. During the first ...